- UAA Congress 2025

Back

Final Presentation Format

Podium Abstract

Eposter Presentation

Eposter in PDF Format

Accept format: PDF. The file size should not be more than 5MB

Eposter in Image Format

Accept format: PNG/JPG/WEBP. The file size should not be more than 2MB

Abstract

Abstract Title

Febuxostat facilitates neovasculogenesis in chronic kidney disease through xanthine oxidase signaling pathways

Presentation Type

Podium Abstract

Manuscript Type

Basic Research

Abstract Category *

Novel Advances: Other Urology Translational Studies

Author's Information

Number of Authors (including submitting/presenting author) *

No more than 10 authors can be listed (as per the Good Publication Practice (GPP) Guidelines).
Please ensure the authors are listed in the right order.

Co-author 1

Chih-Hung Chiang guchiang@gmail.com Kaohsiung Veterans General Hospital Division of Urology, Department of Surgery Kaohsiung Taiwan *

Co-author 2

Ting-Ting Chang tf00619@gmail.com National Yang Ming Chiao Tung University Department and Institute of Pharmacology, School of Medicine Taipei Taiwan

Co-author 3

Co-author 4

Co-author 5

Co-author 6

Co-author 7

Co-author 8

Co-author 9

Co-author 10

Co-author 11

Co-author 12

Co-author 13

Co-author 14

Co-author 15

Co-author 16

Co-author 17

Co-author 18

Co-author 19

Co-author 20

Abstract Content

Introduction

The accumulation of uremic toxins in circulation leads to cardiovascular diseases that result from chronic kidney disease (CKD). This study aimed to investigate febuxostat, a potent xanthine oxidase inhibitor, for its potential effects on the mechanisms of neovasculogenesis in a mouse model of CKD.

Materials and Methods

CKD mice were generated using a 5/6 subtotal nephrectomy and orally administered with febuxostat. We compared with pre-OP and post-OP reactive oxygen species (ROS), renal function, urinary albumin-to-creatinine ratios, and renal inflammatory proteins.

Results

In the CKD mice, febuxostat reduced systemic ROS and preserved kidney function, as evidenced by the reduced levels of serum blood urea nitrogen, creatinine, urinary albumin-to-creatinine ratios, and renal inflammatory proteins. In addition, febuxostat improved neovasculogenesis in an aortic ring assay, a Matrigel plug assay, and a wound healing assay in the CKD mice.

Conclusions

In summary, febuxostat may provide renal protective effects and facilitate neovasculogenesis in CKD in vivo. Further clinical studies may be needed to verify the effects of febuxostat in CKD patients with vascular complications.

Keywords

Febuxostat, neovasculogenesis, chronic kidney disease

Figure 1

Figure 1 Caption

Figure 2

Figure 2 Caption

Figure 3

Figure 3 Caption

Figure 4

Figure 4 Caption

Figure 5

Figure 5 Caption

Presentation Order